Accessibility Menu
Harrow logo

Harrow(NASDAQ) HROW

Current Price$43.34
Market Cap$1.63BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2007)+405%
5 Year+460%
1 Year+18%
1 Month+2%
Harrow last closing stock price
MetricPriceDate
Last closeUSD 43.712026-07-21
Harrow stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+5.66%USD 41.372026-07-14
1 month+1.96%USD 42.872026-06-18
3 month+11.68%USD 39.142026-04-22
Year to date-10.8%USD 49.002025-12-31
1 year+17.88%USD 37.082025-07-21
3 year+100.87%USD 21.762023-07-21
5 year+460.38%USD 7.802021-07-22
Since inception+405.4%USD 8.652007-04-24

Harrow Financials at a Glance

Market Cap

$1.63BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$268.68M

Net Income (TTM)

-$14.96M

EPS (TTM)

-$0.41

P/E Ratio

-106.98

Dividend

$0.00

Beta (Volatility)

1.03 (Average)

Price

$43.34

Volume

7,004

Open

$43.97

Previous Close

$43.71

Daily Range

$42.69 - $43.97

52-Week Range

$28.54 - $54.85

Estimated Earnings Date

Aug 10, 2026

HROW News

SellAlert-Green.png

A Major Investor Just Sold $7.8 Million in Harrow Stock -- Is This a Sell Signal?

Andy GouldMar 24, 2026
BuyAlert-Red.png

Private Equity-Style Fund Buys $15.7 Million in Harrow Stock as Revenue Jumps 45%

Jonathan PoncianoNov 27, 2025
optometrist covering her patient’s eyes with an occluder during an eye exam

Why Shares of Harrow Health Are Jumping Wednesday

James HalleyJul 19, 2023
ophthalmologist eye doctor examines patient

Why Shares of Harrow Health Are Slumping Friday

James HalleyMay 12, 2023

HROW: Motley Fool Moneyball Superscore

72

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Harrow

Harrow makes eye medicines that help people with vision problems like dry eyes or infections. They work with eye doctors to provide affordable treatments that are easy for patients to use. These products help protect sight by treating conditions in both the front and back of the eye.

Treating the Front and Back

  • Branded Pharmaceuticals: FDA-approved drops and injections like Iheezo for numbing and Vevye for dry eye disease.
  • ImprimisRx Compounding: Custom-made eye medicines produced in specialized facilities to meet unique patient needs.
  • Retina Care: Specialized injections like Triesence and biosimilar options used for treating diseases in the back of the eye.
  • Surgery Support: Medications like Ilevro and Nevanac that manage pain and swelling after cataract procedures.

Strategic Deals and Big Plans

  • Acquired the remaining interests of Melt Pharmaceuticals in November 2025 to expand into sedation technologies.
  • Out-licensed Canadian rights for five ophthalmic products to Apotex Inc. in February 2024.
  • Expanded the product portfolio by acquiring commercial rights for several FDA-approved drugs from third parties.
  • Completed Phase 3 clinical trials for a new sedation tablet with a potential commercial launch in 2028.

Why Harrow Stands Out

Harrow runs two specialized pharmacies in New Jersey that make custom medicines not available as standard products. They focus on clinical value to make expensive eye treatments easier for patients to get and afford.

How the Numbers Look

  • Revenue reached $89.1 million in Q4 2025, up 33.3% from $66.8 million in Q4 2024.
  • Gross profit was $70.6 million in Q4 2025, up 34.0% from $52.7 million in Q4 2024.
  • Operating income hit $15.6 million in Q4 2025, up 20.9% year-over-year.
  • Free cash flow improved to $8.1 million in Q4 2025, up 114.6% from Q4 2024.

Bottom Line

Harrow has evolved from a small compounding pharmacy into a broader eye medicine company with several FDA-approved brands. Its growth depends on expanding its product list and managing its specialized pharmacy operations.

AI Generated • Apr 30, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

373

CEO

Mark L. Baum

Website

www.harrow.com

Headquarters

Nashville, TN 37205, US

HROW Financials

Key Financial Metrics (TTM)

Gross Margin

74.11%

Operating Margin

10.47%

Net Income Margin

-5.57%

Return on Equity

-33.65%

Return on Capital

12.68%

Return on Assets

-3.57%

Earnings Yield

-0.93%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.63BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

37.28M

Volume

7.00K

Avg. Volume

829.84K

Financials (TTM)

Gross Profit

$199.11M

Operating Income

$28.12M

EBITDA

$31.47M

Operating Cash Flow

$15.20M

Capital Expenditure

-$926.00K

Free Cash Flow

$14.28M

Cash & ST Invst.

$94.64M

Total Debt

$300.67M

Harrow Performance Analysis

Harrow annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 88,595,00022.2%
20232023-12-31USD 130,193,00047.0%
20242024-12-31USD 199,614,00053.3%
20252025-12-31USD 272,303,00036.4%
Harrow sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3033.3%
Q32025-09-3012.4%
Q42025-12-3124.4%
Q12026-03-31-50.4%
Harrow annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.51-25.7%
20232023-12-31USD -0.7545.9%
20242024-12-31USD -0.49-34.5%
20252025-12-31USD -0.14-71.5%
Harrow sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30126.0%
Q32025-09-30-79.8%
Q42025-12-31587.0%
Q12026-03-31-511.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$44.20M

-7.6%

Gross Profit

$27.05M

-16.3%

Gross Margin

61.18%

N/A

Market Cap

$1.63BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.37M

N/A

Employees

373

N/A

Net Income

-$27.60M

-55.2%

EBITDA

-$16.50M

-146.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$94.64M

+41.8%

Total Debt

$300.67M

+30.7%

Accounts Receivable

$101.26M

+31.0%

Inventory

$16.50M

+53.9%

Long Term Debt

$299.75M

+147.6%

Short Term Debt

$915.00K

-99.2%

Return on Assets

-3.57%

N/A

Return on Invested Capital

8.57%

N/A

Free Cash Flow

-$9.19M

-147.2%

Operating Cash Flow

-$8.99M

-145.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BLFSBioLife Solutions, Inc.
$31.22+6.95%
DVAXDynavax Technologies Corporation
$15.50+0.00%
KMTSKestra Medical Technologies, Ltd.
$21.63-2.74%
ALVOAlvotech
$3.40-3.55%

Trending Stocks

Symbol / CompanyPricePrice Chg
ZCMDZhongchao
$9.35+5.36%
TQQQProShares Trust - ProShares UltraPro Qqq
$71.48+0.00%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$11.21-0.00%
TET1 Energy Inc.
$6.18+0.01%

Questions About HROW

What is the current price of Harrow?

Harrow is trading at $43.34 per share.

What is the 52-week range for Harrow?

Over the past 52 weeks, Harrow has traded between $28.54 and $54.85.

How much debt does Harrow have?

As of the most recent reporting period, Harrow reported total debt of $300.67M.

How much cash does Harrow have on hand?

Harrow reported $94.64M in cash and cash equivalents in its most recent financial results.

What is Harrow’s dividend yield?

Harrow does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services